Investing.com -- Dyne Therapeutics, Inc. (NASDAQ: DYN) reported a second quarter loss that slightly missed analyst expectations as the clinical-stage biotech company continues to advance its ...

The UK’s new industrial strategy signals a decisive shift toward state-backed innovation, investment, and regulatory reform.

On July 24, 2025, the Federal Trade Commission (“FTC”) and the U.S. Department of Justice (“DOJ”) convened the second of ...

Experts from the life sciences industry have shared key insights into how healthcare innovation is changing and the next wave of medicines.The ...

In an exclusive interview with Business Today, D. Sridhar Babu, Minister for Information Technology, Industries and Commerce, ...

Here is a roundup of stories from The Canadian Press designed to bring you up to speed... Bank of Canada expected to hold key rate againBank of Canada ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Each year, the FDA approves a wide range of medications that help shape the future of medicine in the U.S. These include ...

Amgen Inc. (NASDAQ:AMGN) is on the hunt for its next breakthrough drug— a common pursuit among pharmaceutical companies ...

Shares in nuclear medicine play Clarity Pharmaceuticals have surged up to 12% after the company's swift and supersized $203 ...

FDA issued CRLs for RP1 and glofitamab; CB-010 shows promise in lymphoma; osimertinib plus chemo extends NSCLC survival; and ...

Institutional investors including Armistice Capital, RTW Investments, and Wellington Management have increased their exposure ...